Back to Search
Start Over
Mitochondrial aldehyde dehydrogenase activation by Alda-1 inhibits atherosclerosis and attenuates hepatic steatosis in apolipoprotein E-knockout mice.
- Source :
-
Journal of the American Heart Association [J Am Heart Assoc] 2014 Nov 12; Vol. 3 (6), pp. e001329. Date of Electronic Publication: 2014 Nov 12. - Publication Year :
- 2014
-
Abstract
- Background: Mitochondrial dysfunction has been shown to play an important role in the development of atherosclerosis and nonalcoholic fatty liver disease (NAFLD). Mitochondrial aldehyde dehydrogenase (ALDH2), an enzyme responsible for the detoxification of reactive aldehydes, is considered to exert protective function in mitochondria. We investigated the influence of Alda-1, an activator of ALDH2, on atherogenesis and on the liver steatosis in apolipoprotein E knockout (apoE(-/-)) mice.<br />Methods and Results: Alda-1 caused decrease of atherosclerotic lesions approximately 25% as estimated by "en face" and "cross-section" methods without influence on plasma lipid profile, atherosclerosis-related markers of inflammation, and macrophage and smooth muscle content in the plaques. Plaque nitrotyrosine was not changed upon Alda-1 treatment, and there were no changes in aortic mRNA levels of factors involved in antioxidative defense, regulation of apoptosis, mitogenesis, and autophagy. Hematoxylin/eosin staining showed decrease of steatotic changes in liver of Alda-1-treated apoE(-/-) mice. Alda-1 attenuated formation of 4-hydroxy-2-nonenal (4-HNE) protein adducts and decreased triglyceride content in liver tissue. Two-dimensional electrophoresis coupled with mass spectrometry identified 20 differentially expressed mitochondrial proteins upon Alda-1 treatment in liver of apoE(-/-) mice, mostly proteins related to metabolism and oxidative stress. The most up-regulated were the proteins that participated in beta oxidation of fatty acids.<br />Conclusions: Collectively, Alda-1 inhibited atherosclerosis and attenuated NAFLD in apoE(-/-) mice. The pattern of changes suggests a beneficial effect of Alda-1 in NAFLD; however, the exact liver functional consequences of the revealed alterations as well as the mechanism(s) of antiatherosclerotic Alda-1 action require further investigation.<br /> (© 2014 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
- Subjects :
- Aldehyde Dehydrogenase genetics
Aldehyde Dehydrogenase, Mitochondrial
Animals
Aorta enzymology
Aorta pathology
Aortic Diseases blood
Aortic Diseases enzymology
Aortic Diseases genetics
Aortic Diseases pathology
Apolipoproteins E genetics
Atherosclerosis blood
Atherosclerosis enzymology
Atherosclerosis genetics
Atherosclerosis pathology
Biomarkers blood
Disease Models, Animal
Enzyme Activation
Female
Gene Expression Regulation
Hep G2 Cells
Humans
Liver enzymology
Liver pathology
Mice, Inbred C57BL
Mice, Knockout
Mitochondria, Liver enzymology
Non-alcoholic Fatty Liver Disease blood
Non-alcoholic Fatty Liver Disease enzymology
Non-alcoholic Fatty Liver Disease genetics
Non-alcoholic Fatty Liver Disease pathology
Signal Transduction drug effects
Aldehyde Dehydrogenase metabolism
Aorta drug effects
Aortic Diseases prevention & control
Apolipoproteins E deficiency
Atherosclerosis prevention & control
Benzamides pharmacology
Benzodioxoles pharmacology
Enzyme Activators pharmacology
Liver drug effects
Mitochondria, Liver drug effects
Non-alcoholic Fatty Liver Disease prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 2047-9980
- Volume :
- 3
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Journal of the American Heart Association
- Publication Type :
- Academic Journal
- Accession number :
- 25392542
- Full Text :
- https://doi.org/10.1161/JAHA.114.001329